The INNOVANCE® PFA-200 System offers rapid detection and automated assessment for inherited, acquired, or drug-induced platelet dysfunction.
The new INNOVANCE PFA-200 System1 from Siemens uses state-of-the-art technology for rapid in vitro testing of platelet function, simulating hemodynamic flow conditions of platelet adhesion and aggregation in a vascular lesion. The system measures platelet plug formation in a small whole blood sample (800µL), and reports a "closure time" in five to eight minutes. The INNOVANCE PFA-200 System offers sensitive detection of acquired, inherited, or drug-induced platelet dysfunction in multiple clinical settings. It serves as a valuable adjunct for the optimized clinical outcome of therapeutic interventions, and supports decision-making algorithms in transfusion medicine.
Detects inherited, acquired, and drug-induced platelet dysfunction
It also serves as an adjunct in the potential outcome of therapeutic intervention in the avoidance of mortality rates, and in decision-making in transfusion medicine. In combination with traditional coagulation screening tests, such as Prothrombin Time and Activated Partial Thromboplastin Time, the INNOVANCE PFA-200 System provides the appropriate level of sensitivity to functional defects of hemostasis. Through preoperative detection of patients with impaired primary hemostasis and convenient monitoring of presurgical therapy, the system can effectively support preoperative bleeding risk management.
Detection of aspirin-induced platelet dysfunction
Additionally, the INNOVANCE PFA-200 System can check whether cardiovascular patients on aspirin therapy experience the therapeutic benefit from this medication by demonstrating aspirin-induced platelet function inhibition. While most other analyzers only measure the effect on platelet aggregation, the Siemens’ analyzer accurately measures the prevention ability of aspirin against platelet plug formation.
Some common “screening tests” may fail to detect a number of mild bleeding disorders that could cause substantial bleeding. In contrast, the PFA-200 system has been shown to effectively identify patients with a bleeding risk due to platelet function deficiency. With the INNOVANCE PFA-200 System, most patients with prolonged closure times manifest abnormalities in primary hemostasis that could place them at risk for bleeding and transfusion needs during and after surgery.
Not available for sale in the U.S.